PIK3CA and neoplasm: The fact that PI3K/AKT activating mutations commonly co-occur with other genetic alterations2, and that new MAPK-reactivating mutations are acquired in resistant tumours with pre-existing PI3K/AKT activating mutations indicate that PI3K/AKT signalling favours the selection and expansion of resistant tumour subclones.